For patients demonstrating ypN1 disease on SLNB following neoadjuvant chemotherapy, is it reasonable to proceed with regional RT in lieu of AxLND outside of the ALLIANCE A011202 trial?

Ideally these patients should go on the Alliance A011202 trial or have a full dissection as the current standard. AMAROS and other studies clearly have shown that radiation to the axilla is highly effective compared to axillary dissection for patients with a positive sentinel node at initial diagnos...